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Mutations in CDON, Encoding a Hedgehog Receptor,
Result in Holoprosencephaly and Defective
Interactions with Other Hedgehog Receptors
Gyu-Un Bae,1,2,4,6 Sabina Domene´,3,4,7 Erich Roessler,3 Karen Schachter,1,8 Jong-Sun Kang,2,5,*
Maximilian Muenke,3,5,* and Robert S. Krauss1,5
Holoprosencephaly (HPE), a common human congenital anomaly defined by a failure to delineate the midline of the forebrain and/or
midface, is associated with diminished Sonic hedgehog (SHH)-pathway activity in development of these structures. SHH signaling is
regulated by a network of ligand-binding factors, including the primary receptor PTCH1 and the putative coreceptors, CDON (also called
CDO), BOC, and GAS1. Although binding of SHH to these receptors promotes pathway activity, it is not known whether interactions
between these receptors are important. We report here identification of missense CDON mutations in human HPE. These mutations
diminish CDON’s ability to support SHH-dependent gene expression in cell-based signaling assays. The mutations occur outside the
SHH-binding domain of CDON, and the encoded variant CDON proteins do not display defects in binding to SHH. In contrast,
wild-type CDON associates with PTCH1 and GAS1, but the variants do so inefficiently, in a manner that parallels their activity in
cell-based assays. Our findings argue that CDONmust associate with both ligand and other hedgehog-receptor components, particularly
PTCH1, for signaling to occur and that disruption of the latter interactions is a mechanism of HPE.Introduction
Holoprosencephaly (HPE [MIM 236100]) comprises a clin-
ical spectrum of related malformations of the brain and
face that reflect gradations of disrupted developmental
midline patterning.1 HPE occurs with a remarkably high
frequency, in at least one in every 250 conceptions.2 Path-
ogenic causes include environmental factors, such as
teratogens, and genetic factors, including clinically
distinct syndromes, micro- and macro-cytogenetic alter-
ations, and single gene mutations in at least nine genes.3
Single gene mutations are always heterozygous and, where
tested, result in loss of function.3 The genetic heteroge-
neity of the HPE spectrum of disorders is considerable, as
is the variable expressivity of pathogenic mutations, even
within the same family. To a large extent, the molecular
basis of this variability is unknown. However, the best
understood mechanisms for HPE-like malformations are
defects in various components of the Sonic hedgehog
(SHH [MIM 600725])-signaling pathway.3,4
The binding of SHH to its primary receptor PTCH1 (MIM
601309) activates a signal transduction cascade that culmi-
nates in expression of pathway target genes via the GLI
family of transcription factors.5,6 Among the direct target
genes are PTCH1 and GLI1 (MIM 165220) themselves.5,6
Additional membrane-associated SHH-binding proteins
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The AmericPTCH1. For example, the related IgSF proteins CDON
(MIM 608707) and BOC (MIM 608708) and the GPI-linked
factor GAS1 (MIM 139185) each interact directly with
SHH7–12 and individually associate with PTCH1.13
Although binding of SHH to these receptors promotes
pathway activity, it is not known whether interactions
between the receptors are important.
Cdon/ mice display HPE with strain-specific severity
and have phenotypes ranging from severe to mild depend-
ing on the genetic background.14,15 Although Boc/ mice
do not have HPE and Gas1/ mice have mild HPE,
Cdon/;Boc/ and Cdon/;Gas1/ double mutants
display more severe forms of HPE than any single mutant,
suggesting that these factors may cooperate to promote
SHH-mediated patterning of the rostroventral mid-
ine.16,17 Because the mouse-strain-dependent variability
in penetrance and expressivity of HPE phenotypes in
Cdon/ mice resembles the variability seen in human
HPE, CDON is a strong candidate to be an HPE-associated
factor. We report here the identification of missense
CDON mutations in human HPE. The mutations result in
diminished activity in SHH-signaling assays, consistent
with a significant role for this coreceptor in HPE pathogen-
esis. Furthermore, we find that CDON associates with
PTCH1 and GAS1, but the HPE-associated variants do so
inefficiently in a manner that parallels their activity in
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associate with other hedgehog-receptor components for
signaling to occur and that disruption of such interactions
is a mechanism of HPE.Material and Methods
Human DNA Samples and SNP Detection
We studied 282 unrelated individuals diagnosed with HPE spec-
trum disorders and 96 commercially available anonymous normal
controls. Genomic DNA was extracted from peripheral blood or
transformed lymphoblast cell lines by standard methods. All indi-
viduals with HPE were recruited into a National Human Genome
Research Institute institutional-review-board-approved research
protocol in accordance with their ethical guidelines and supervi-
sion. All probands and available parents were studied for relevant
coding-region alterations and their inheritance in the four genes
most commonly screened in HPE (SHH, ZIC2, SIX3, and TGIF)
by bidirectional Big Dye version 3.1 terminator cycle sequencing
on an ABI 3100 instrument (Applied Biosystems, Foster City,
CA) as described.18
Mutation detection for CDON was performed by PCR-based
denaturing high performance liquid chromatograhy (dHPLC)
analysis followed by direct sequencing. PCR amplification, dHPLC
analysis employing WAVE and WAVEMAKER (Transgenomic,
Omaha, NE), amplicon purification with the QIAGEN PCR purifi-
cation kit (QIAGEN, Valencia, CA), and DNA sequencing with the
Big Dye version 3.1 terminator cycle sequencing on an ABI 3100
instrument were performed according to the manufacturers’
instructions, essentially as previously described.19 We then
compared our research findings to those described in publicly
available databases (dbSNP and 1000 Genomes) as summarized
in Table S1, available online.
For this study we used the reference sequence NM_016952.4
comprising 19 coding exons of human CDON. PCR was performed
with primer pairs and conditions listed in Table S2. In brief, we per-
formed amplificationof genomicDNA in 35 ml reactionvolumes by
using 60–100 ng of genomic DNA, 200 mM dNTP, 20 pmol of each
primer, 13 PCR buffer (Invitrogen, Carlsbad, CA), 0.53 enhancer
(Invitrogen), 1.5 mM MgSO4 (Invitrogen), and 2.5 U of AmpliTaq
(Applied Biosystems). All reactions were performed in a PTC-225
thermocycler (MJ Research, Waltham, MA). PCR-cycling parame-
terswere (1) 95Cfor 4min; (2) 50 cycles of 95Cfor 30 s, an anneal-
ing temperature (Table S2) for 30 s, and 72C for 1 min; and (3)
a final step of 72C for 7 min. After amplification, PCR products
were denatured at 96C for 1min, followed by gradual reannealing
to 65C over a period of 30 min to form homo- and/or heterodu-
plexes. Products were automatically loaded on a DNA sep column
and eluted according to the manufacturer’s instructions at a flow
rate of 1.5 ml/min with a mixture of buffer A (0.1 mM TEAA) and
buffer B (0.1mMTEAA and 25%acetonitrile); the amount of buffer
Bwas increased 10%perminute for 2.5min. Sampleswere detected
by anultravioletC system.Wedetermined the oven temperature(s)
for optimal heteroduplex separation under partial DNA denatur-
ation for each amplified fragment by using the WAVEMaker
software (version4.1) and adjusted empirically. Because the dHPLC
approach is based on the differential retention of homo- and
heteroduplex DNA fragments by ion-pair chromatography under
conditions of partial heat denaturation, optimal discrimination
of double-stranded combinations depends on the temperature at
which partial denaturation of heteroduplexes occur. Most ampli-
cons were composed of different melting domains; thus more232 The American Journal of Human Genetics 89, 231–240, August 1than one elution temperature was needed to detect the variants.
The data profiles of all samples were analyzed by visual inspection,
and those with clear or suggestive variant peaks were sequenced
with the same primers as used for PCR. The dHPLC screening
method detects at least 96% of the sequence variation of a test
amplicon20 but is not as specific as Sanger sequencing for allele
discrimination.Cell-Culture and Expression Vectors
C2C12, 293T, Cos7, RD, and 10T1/2 cells were cultured as previ-
ously described.21,22 Mouse embryo fibroblast lines derived from
Cdon/ mice were derived and cultured with standard proto-
cols.23 For SHH-signaling assays, cells were reverse transfected
with plasmids diluted in Opti-MEM with Lipofectamine 2000
(Invitrogen) in individual wells of 6-well plates. Cells were added
to 80%–90% confluence; transfection efficiency was 80%–90%.
Plasmids were either previously published expression vectors
encoding rat CDON,24 human BOC,25 human PTCH1,26 and
mouse Cdon siRNA15 or a mouse GAS1 expression vector; the
mouse Gas1 cDNA was cloned by RT-PCR. Vectors encoding rat
CDON variants were constructed by PCR mutagenesis27 with
pBabePuro-rCDON as a template and were verified by sequencing
(primers used are described in Table S4). Vectors encoding CDON-
Fc and CDON proteins with specific ectodomain deletions were
described previously.25,28Immunoblot Analysis and Immunoprecipitation
Immunoblot analyses were carried out as previously described.29
Briefly, cells were lysed in lysis buffer (10 mM Tris-HCl [pH 7.2],
150 mM NaCl, 1% Triton X-100, and 1 mM EDTA) containing
Complete Protease Inhibitor Cocktail (Roche Diagnostics),
followed by SDS-PAGE. Primary antibodies used in this study
were anti-CDON, anti-BOC, anti-GAS1 (R&D Systems), anti-
b-tubulin (Zymed), anti-flag (Sigma Aldrich), anti-human Fc
region of IgG (Jackson Immunoresearch), and anti-PTCH1 (Santa
Cruz). Coimmunoprecipitations were performed as described
previously.29 Quantification of coimmunoprecipitations was per-
formed with Image-Gauge software (Fuji Film, Tokyo, Japan).
Results are expressed as mean 5 standard deviation (SD) from at
least three independent experiments and analyzed by Student’s
t test using SPSS (version 12.0; SPSS, Chicago, IL, USA).RNA Extraction and Quantitative RT-PCR
For analysis of Ptch1 and Gli1 mRNA levels after SHH treatment,
10T1/2 cells orCdon/mouse embryonic fibroblasts (MEFs) trans-
fected with the indicated expression vectors were grown in Dul-
becco modified Eagle medium (DMEM) containing 10% fetal
bovine serum. Twenty-four hours after transfection, near
confluent cultures were changed to DMEM plus 2% horse serum
and treated with recombinant SHH (R&D Systems) (400 ng/ml)
for 24 hr. Total RNA was extracted using easy-Blue reagent
(iNtRON Biotechnology, Kyunggi-do, South Korea). The cDNAs
were reverse-transcribed from one mg of total RNA with oligo-dT
primer and SuperScript II reverse transcriptase (Invitrogen). PCR
reactions were performed with 5% of the reverse transcription
(RT) reaction, 250 nM of each primer, and SYBR Premix Ex Taq
polymerase (Takara). PCR reactions were performed on an ABI
PRISM 7000 Sequence Detection System (Applied Biosystems).
Expression levels of Gapdh were used to normalize the expression
levels of each sample. Primer sequences used were as described
previously.152, 2011
Table 1. Clinical and Molecular Findings of Individuals with CDON Mutations
Patient Number CDON Variation Amino Acid Inheritance Clinical Findings
5410 c.2051C>G p.Thr684Ser maternal; both parents tested aborted fetus, referred for HPE findings.
7190 c.2065C>G p.Pro689Ala unknown; parents unavailable agenesis of the corpus callosum,
hypotelorism, growth hormone deficiency,
global developmental delay; dark, thick
eyebrows with synophrys.
5308 c.2071G>A p.Val691Met maternal by clinical history;
parents not available
suspected autosomal dominant HPE,
microcephaly, developmental delay; half-sib
died at two months of semi-lobar HPE and
biliary atresia.
6864 c.2339T>A p.Val780Glu unknown; mother negative,
father unavailable
HPE-like, midline cyst of falx cerebri.
5288 c.2368A>G p.Thr790Ala de novo; both parents tested agenesis of the corpus callosum, alobar HPE,
hypotelorism, mild proptosis, median cleft
lip/palate, absent columella, cryptorchidism.
at autopsy: incomplete separation of the
frontal lobes, absent pituitary, adrenal
atrophy, absent corpus callosum, optic tracts
with single cerebral artery. hepatic
cholestasis and polysplenia noted.
7321 c.2818A>C p.Ser940Arg unknown; mother negative,
father unavailable
alobar HPE findings.Determination of CDON Protein Half-Lives
We transfected Cdon/ MEFs with expression vectors encoding
wild-type (WT)CDONandCDONvariants by using Lipofectamine
2000. Forty-eight hours after transfection, cells were treated with
10 mM cycloheximide and harvested at various time points there-
after. Cell lysates were analyzed by immunoblotting for CDON,
and, as a loading control, b-actin. CDON levels were quantified
by densitometry with ImageJ software, normalized to actin levels,
and compared to untreated samples. Half-lives reported are aver-
ages of three experiments. Data were analyzed by Student’s t test.
SHH-N::AP Cell-Surface-Binding Assays
Experiments were performed as previously described.11 In brief,
Cos7 cells were transfected with expression vectors for WT
CDON or CDON variants with Lipofectamine 2000. Forty-eight
hours after transfection, cells were washed with PBS and incubated
with increasing concentrations of ShhN::AP for 90 min at room
temperature. Cells were washed extensively with PBS, fixed with
PFA, and bound AP activity was measured with AP yellow liquid
substrate (Sigma). Saturation binding curves and Scatchard anal-
yses were performed with GraphPad Prism software. Experiments
were performed at least three times and Kd values were determined
by fitting each data set to the one-site-specific binding model by
nonlinear regression.Results
We analyzed 282 unrelated individuals with HPE spectrum
disorders and 96 anonymous controls for sequence varia-
tions of CDON. A total of 44 distinct sequence variations
were identified within the amplicons tested (Tables S1
and S2), of which 24 were not previously described; one
variant was also seen in a cohort with a different
anomaly.30 We chose to focus on the rare variants that
were not detected in public databases or in our anonymousThe Americcontrol cohort. Six heterozygous missense mutants found
only in HPE cases were chosen for further study: (1)
c.2051C>G (p.Thr684Ser), (2) c.2065C>G (p.Pro689Ala),
(3) c.2071G>A(p.Val691Met), (4) c.2339T>A(p.Val780Glu),
(5) c.2368A>G (p.Thr790Ala), and (6) c.2818A>C
(p.Ser940Arg) (see the clinical summary in Table 1 and
Figure 1A). Although information on parental genotypes
was limited, at least onemutationwas a denovo occurrence
in the affected individual (p.Thr790Ala; Table 1).
To assess the functional consequences of the six HPE-
associated CDON mutations, we engineered equivalent
mutations into a rat Cdon cDNA and performed cell-based
assays (the corresponding human and rat mutations and
their positions within CDON are shown in Figure 1A).
Expression of WT CDON in Cdon/ MEFs conferred
SHH-dependent induction of the endogenous Ptch1 and
Gli1 (Figures 1A and 1C). Expression of the p.Pro686Ala,
p.Val777Glu, p.Ile787Ala, and p.Ser937Arg variants failed
to support induction of Ptch1 and Gli1 in this system,
revealing them to be defective in ligand-initiated pathway
activity; in contrast, the p.Thr681Ser and p.Val688Met
variants were as active as WT CDON in this assay (Figures
1B–1D). Similar results were obtained with 10T1/2 cells,
except that the p.Ile787Ala substitution was only partially
defective (Figure S1). p.Thr681Ser may correspond to a
rare human SNP;30 p.Val688Met may also be a rare,
benign variant, or it may affect CDON function in a way
not revealed by this assay. The ability of the defective
variants to promote SHH signaling was dose dependent,
because transfection of 2.5 times the amount of plasmid
used in Figure 1B–1D and Figure S1 revealed that when
expressed at this level, the p.Val777Glu, p.Ile787Ala, and
p.Ser937Arg substitutions possessed 35%–75% the activity
of WT CDON in Cdon/ MEFs; p.Pro686Ala was stillan Journal of Human Genetics 89, 231–240, August 12, 2011 233
Figure 1. CDON HPE Variants Do Not Support
SHH-Dependent Gene Expression
(A) Schematic diagram of CDON and the location
of HPE-associated variants. The missense CDON
variants from human HPE cases (hCDON) and
the corresponding residues engineered into a rat
Cdon (rCDON) cDNA are shown at the right.
The p.Thr684Ser and p.Thr681Ser (T684S and
T681S), p.Pro689Ala and p.Pro686Ala (P689A
and P686A), and p.Val691Met and p.Val688Met
(V691M and V688M) variants are in the linker
region between Fn repeats 1 and 2. The
p.Val780Glu and p.Val777Glu (V780E and
V777E) and the p.Thr790Ala and p.Ile787Ala
(T790A and I787A) variants are in Fn repeat 2.
The p.Ser940Arg and p.Ser937Arg (S940R and
S937R) variants are in the linker region between
Fn repeat 3 and the transmembrane (TM) region.
SHH binds to Fn repeat 3.
(B and C) qRT-PCR analysis of Ptch1 (B) and Gli1
(C) expression in Cdon/ MEFs transfected with
2 mg of the indicated CDON vectors plus or minus
treatment with SHH. Expression was normalized
to Gapdh.
(D) qRT-PCR analysis of expression of CDON
variants in Cdon/ MEFs from same lysates
analyzed in (B and C).
Error bars represent the means of triplicate deter-
minations5SD. **p < 0.01 as compared to wild-
type CDON.largely inactive even at the higher dose (Figure 2). Again,
similar results were seen with 10T1/2 cells (Figure S2).
Therefore, these mutations appear to be loss-of-function
but not null. We also analyzed this cohort for changes
in the four genes most commonly studied in HPE18
(SHH, SIX3 [MIM 603714], ZIC2 [MIM 603073],and TGIF
[MIM 602630]), and of those individuals withCDONmuta-
tions, only one had a mutation in these genes (Table S3);
our study subject with the p.Val691Met variation
(p.Val688Met in the rat construct that behaved normally
in functional assays) had an alanine tract expansion in234 The American Journal of Human Genetics 89, 231–240, August 1ZIC2 that is most likely a pathological alteration.31,32
Therefore, the four individuals with loss-of-function
CDON mutations did not harbor additional mutations in
the genes most often associated with HPE.
To begin to address the molecular properties of the
HPE-associated variant CDON proteins, their half-
lives and ability to bind SHH were quantified. The half-
lives of WT CDON and the p.Thr681Ser, p.Pro686Ala,
p.Val688Met, and p.Ile787Ala variants were all ~2 hr,
whereas the half-lives of p.Val777Glu and p.Ser937Arg
were ~34% shorter than that (Table 2). Furthermore,Figure 2. Overexpression Reveals Partial Loss
of Function in Some CDON Variants
(A and B) qRT-PCR analysis of Ptch1 (A) and Gli1
(B) expression in Cdon/ MEFs transfected with
5 mg of the indicated CDON vectors plus or minus
treatment with SHH. Expression was normalized
to Gapdh. Error bars represent the means of tripli-
cate determinations5SD. **p< 0.01, *p< 0.05 as
compared to WT CDON.
(C) Immunoblot analysis of CDON expression in
10T1/2 cells under the conditions used in
(A and B).
CDON variants are designated as in Figure 1.
2, 2011
Table 2. Properties of HPE-Associated CDON Variants
CDON Variant Half-Life (hr)
Dissociation Constant (Kd)
for ShhN::AP (nM)
WT CDON 2.03 5 0.23 5.52 5 1.13
p.Thr681Ser 2.22 5 0.21 3.12 5 1.16
p.Pro686Ala 2.22 5 0.51 3.14 5 1.18
p.Val688Met 2.89 5 0.65 2.03 5 0.19
p.Val777Glu 1.36 5 0.21a 9.26 5 3.16
p.Ile787Ala 2.23 5 0.47 1.54 5 0.63
p.Ser937Arg 1.34 5 0.21a 4.05 5 1.71
a p < 0.05.when the CDON variants were immunoprecipitated under
conditions of limited proteolysis, p.Val777Glu and
p.Ser937Arg revealed distinct products not seen with WT
CDON or the variants with a normal half-life (Figure S3).
These results suggest that p.Val777Glu and p.Ser937Arg
have an altered conformation that may partially destabi-
lize them and contribute to their loss of function.
To determine the ability of CDON HPE variants to bind
SHH ligand, a soluble SHH-N::AP fusion protein (consisting
of theN-terminal portion of SHHwith alkaline phosphatase
fused to its carboxy terminus) was used in saturation
binding experimentswith cells that expressedWTor variant
forms of CDON. Dissociation constants (Kd) for binding of
SHH-N::AP to WT CDON and all variants were in the low
nanomolar range (Table 2 and Figure S4), similar to the find-
ings inaprevious report.11Moreover, thevariation inKd that
existed among the CDON variants did not correlate with
their abilities to promote SHH-initiated induction of Ptch1
orGli1 inCdon/MEFs or 10T1/2 cells as shown in Figure 2
and Figure S2 (R ¼ 0.17–0.24; Figure S5). This is consistent
with the fact that none of the mutations occurred in Fn(3),
the SHH-binding repeat of CDON11,12 (Figure 1A), and indi-
cates that the variants’ defective ability to support SHH-
dependent gene expression is unlikely to be due to dimin-
ished ability to associate with ligand.
Because the CDON HPE variants were not defective in
binding to SHH, we assessed their ability to bind other
components of the signal reception machinery, including
PTCH1, BOC, GAS1, and WT CDON itself, in coimmuno-
precipitation experiments. CDON and PTCH1 coimmuno-
precipitated both endogenously and in transfectants
(Figure 3A and Figure S6). Three of the four variants
defective in promoting SHH signaling (p.Pro686Ala,
p.Val777Glu, and p.Ser937Arg) displayed significantly
diminished ability to coprecipitate with PTCH1 (Figures
3A and 3B). These experiments require a level of trans-
fected vector similar to that used in the Cdon/-MEF-
based and 10T1/2-cell-based functional assays shown in
Figure 2 and Figure S2, where partial loss of function of
the HPE-associated variants was observed. In contrast to
the lack of correlation with SHH binding, the diminishedThe Americactivities of the variants in these assays correlated very
well with their reduced level of binding to PTCH1 (R ¼
0.88–0.99, p ¼ 0.008–< 0.001; Figure S5). CDON has also
been shown to interact with itself and with BOC,25,33 but
the CDON HPE variants did not display any defect in
binding to WT CDON (Figure S7) and only p.Pro686Ala
showed decreased ability to associate with BOC in coim-
munoprecipitations (Figures 3C and 3D).
CDON has not previously been shown to associate with
GAS1. Endogenous GAS1 coimmunoprecipitated with
endogenous CDON and the presence of GAS1 in the
precipitate was strongly diminished by depletion of
CDON by RNAi, indicating the specificity of the interac-
tion (Figure 3E and Figure S8). GAS1 also coimmunopreci-
pitated with BOC (Figure S8). The amount of GAS1 that
coprecipitated with CDON was not significantly altered
by pretreatment of the cells with SHH-N (Figure S8). Coim-
munoprecipitation was also observed when GAS1 was
ectopically coexpressed with the CDON or BOC ectodo-
mains in 293T cells (Figure S8). The ability of HPE-associ-
ated CDON variants to interact with GAS1 was therefore
assessed in cotransfectants. Three of the four variants
defective in promoting SHH signaling (p.Pro686Ala,
p.Ile787Ala, and p.Ser937Arg) displayed significantly
diminished ability to coprecipitate GAS1 (Figures 3F and
3G), and the reduction in GAS1 binding correlated with
their reduction in activity in the Cdon/-MEF-based and
10T1/2-cell-based assays (R ¼ 0.73–0.90, p ¼ 0.06–0.005;
Figure S5), though not as strongly as PTCH1 binding did.
If the diminished binding to GAS1 (and to BOC for
p.Pro686Ala) was critical to the CDON variants’ loss of
function, these receptors might be predicted to synergize
to promote SHH ligand-dependent pathway activity.
However, coexpression of combinations of any two or all
three coreceptors in Cdon/MEFs or 10T1/2 cells revealed
largely additive effects (Figure 4 and Figure S9). Further-
more, expression of CDON HPE variants did not inhibit
the activity of GAS1 plus BOC to stimulate SHH-dependent
induction of Gli1 or Ptch1 in 10T1/2 cells or in Cdon/
MEFs, suggesting that these variants do not possess a domi-
nant inhibitory activity toward WT (endogenous) CDON
or the other coreceptors (Figure 4 and Figure S9).
CDON binds to PTCH1 via both the Fn(1) and Fn(2)
repeats in its ectodomain.13 So that we could determine
the specific CDON ectodomain repeat(s) involved in
binding to BOC, GAS1, and CDON itself, cells were co-
transfected to express a series of secreted CDON extracel-
lular region-Fc fusion proteins and either BOC, GAS1, or
WT CDON. The CDON-Fc proteins were pulled down
and immunoblotted for Fc and either BOC, GAS1, or
CDON. In these experiments, we found that Fn(2) bound
to GAS1; Fn(2) and, to a lesser extent, Fn(3) bound to
BOC; and full-length CDON associated efficiently with
a CDON-Fc construct containing all three Fn repeats but
more weakly with the individual Fn(2) and Fn(3) repeat
constructs (Figures 5A–5D). Fn(3), which is necessary
and sufficient for binding SHH, is required for CDONan Journal of Human Genetics 89, 231–240, August 12, 2011 235
Figure 3. CDON Variants Display Dimin-
ished Interaction with Other SHH-Binding
Proteins
(A) Cos7 cells were transfected with an
expression vector encoding flag-tagged
PTCH1 (þ) or a control vector () and
expression vectors encoding CDON, the
indicated CDON variants, or a control
vector (pBp) as indicated. Lysates were
immunoprecipitated with antibodies to
flag epitope and immunoblotted with
antibodies to flag or CDON. Lysates were
also blotted as a control.
(B) Results from three independent experi-
ments were quantified for the amount of
CDON that immunoprecipitated with
PTCH1.
(C) 293T cells were transfected with an
expression vector encoding BOC (þ) or
a control vector () and expression vectors
encoding CDON, the indicated CDON
variants, or a control vector (pBp) as indi-
cated. Lysates were immunoprecipitated
with antibodies to the CDON intracellular
region and immunoblotted with anti-
bodies to CDON or BOC. Lysates were
also blotted as a control.
(D) Results from three independent exper-
iments were quantified for the amount
of BOC that immunoprecipitated with
CDON.
(E) 10T1/2 or C2C12 cell lysates were
immunoprecipitated with antibodies to
CDON and immunoblotted with anti-
bodies to CDON and GAS1. Lysates were
immunoblotted as a control.
(F) 293T cells were transfected with an
expression vector encoding GAS1 (þ) or
a control vector () and expression vectors
encoding CDON, the indicated CDON
variants, or a control vector (pBp) as indi-
cated. Lysates were immunoprecipitated
with antibodies to the CDON intracellular
region and immunoblotted with antibodies to CDON or GAS1. Lysates were also blotted as a control.
(G) Results from three independent experiments were quantified for the amount of GAS1 that immunoprecipitated with CDON.
CDON variants are designated as in Figure 1. Error bars represent the means of triplicate determinations5SD. **p < 0.01, *p < 0.05 as
compared to wild-type CDON.activity.11,12 We investigated the requirements of Fn(1)
and Fn(2), involved in CDON binding to PTCH1 and
GAS1, through use of CDON deletion mutants that lacked
either or both domains. Removal of Fn(1) reduced CDON’s
ability to promote SHH-dependent induction of Gli1 and
Ptch1 in Cdon/ MEFs by less than 50%, whereas loss of
Fn(2) reduced activity by ~70% and removal of both
Fn(1) and Fn(2) reduced activity by ~85% (Figures 5E–
5G). These results indicate that the Fn repeats that interact
with PTCH1 and other SHH receptors, particularly Fn(2),
are important for CDON function.
Discussion
We report here the identification of CDON mutations in
individualswithHPE. TheHPE spectrumofdefects is charac-
terized by a very broad range of phenotypic severity. Studies
with Cdon mutant mice recapitulate these characteristics236 The American Journal of Human Genetics 89, 231–240, August 1because these animals display HPE with strain-dependent
severity.14,15 The CDON mutations identified are typical of
those generally associated with HPE in that they are hetero-
zygous and result in a loss of ability to promote SHH
signaling. Additionally, at least one such mutation was
a de novo occurrence in the affected individual (Table 1).
Taken together, these results argue persuasively that CDON
mutations are important contributing factors to HPE.
Defects in the SHH pathway are the most common
known cause of HPE, and our analysis of HPE-associated
CDON mutations provides insight into mechanisms of
hedgehog signaling. The mutations reported here did not
occur in Fn(3), the CDON ectodomain repeat that binds
directly to SHH, and they did not result in obvious defects
in ability to confer cell-surface binding of a recombinant
form of SHH. In contrast, we find that these CDON vari-
ants associated inefficiently with two other proteins that
bind SHH to the cell-surface, the primary receptor PTCH12, 2011
Figure 4. CDON, BOC, and GAS1 Have Roughly Additive Activity in Promoting SHH-Dependent Gene Expression
(A and B) qRT-PCR analysis of Ptch1 and Gli1 expression in Cdon/MEFs transfected with 2 mg of the indicated CDON, BOC, and GAS1
expression vectors plus or minus treatment with SHH. Expression was normalized to Gapdh.
(C) qRT-PCR analysis of expression of CDON variants in Cdon/ MEFs from same RNA samples analyzed in (A and B).
(D) Immunoblot analysis of CDON, BOC, and GAS1 expression inCdon/MEFs transfected with 5 mg of CDON, BOC, and GAS1 expres-
sion vectors.
CDON variants are designated as in Figure 1. Error bars represent the means of triplicate determinations5SD. **p< 0.01 as compared to
wild-type CDON.and the coreceptor GAS1, in a manner that paralleled their
diminished activity in SHH-signaling assays. This was
specific as the variants associated normally with two
different SHH coreceptors, BOC and WT CDON itself
(the one exception was a decrease in the ability of the
p.Pro686Ala substitution to associate with BOC). These
results indicate that interaction between proteins that
bind SHH to the cell-surface is an important aspect of
SHH signal reception.
Studies with mice carrying mutations in Cdon, Boc, and
Gas1, singly or in combination, lead to the conclusion
that: (1) these factors have both specific and overlapping
functions; (2) no single factor is essential for hedgehog-
pathway activity; and (3) they are collectively required
for hedgehog-pathway function in that combined loss
of all three factors results in a nearly complete loss of
pathway activity in the early embryo.16,17,34 Furthermore,
a SHH point mutant that binds PTCH1 but not CDON,
BOC, or GAS1 is unable to activate hedgehog-pathway
signaling.13 These studies are consistent with a model
whereby SHHmust engage PTCH1 and at least one of these
coreceptors to activate signaling. However, whether the
coreceptors need to interact with PTCH1 and/or each other
has not been addressed. The selectively reduced ability of
the HPE-associated CDON variants to interact with
PTCH1 and GAS1 argues that interactions between SHH
receptors are important for signaling. Taken together, theThe Americresults are consistent with the notion that CDON (and
presumably BOC and GAS1) must associate with both
ligand and other hedgehog-receptor components, particu-
larly PTCH1, for signaling to occur. The fact that mice
lacking any two of CDON, BOC, or GAS1 still display
a significant, though very obviously diminished, level of
SHH-dependent embryonic patterning argues that these
factors share at least some redundant or compensatory
activity.16,17,34 Our finding that these three factors func-
tion largely additively to promote SHH signaling in trans-
fectants is consistent with this conclusion. The diminished
binding to PTCH1 displayed by the HPE-associated CDON
variants is therefore likely to be a more important func-
tional defect than diminished binding to GAS1 in their
loss of activity, though the latter may also contribute.
In summary, it is concluded that mutation-induced
disruption of interactions between components of the
hedgehog-reception machinery is a mechanism of HPE.
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